Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.

Autor:	Park YH; Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea., Kim DY; Department of Internal Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University School of Medicine, Seoul, Korea., Mun YC; Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea., Cho EK; Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea., Lee JH; Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea., Jo DY; 4 Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea., Kim I; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea., Yoon SS; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea., Park SY; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea., Kim B; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea., Bang SM; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea., Kim H; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea., Min YJ; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea., Park JH; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea., Seo JJ; Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea., Moon HN; Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea., Lee MH; Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea., Kim CS; Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea., Lee WS; Department of Hemato/Oncology, Inje University Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea., Chong SY; Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea., Oh D; Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea., Zang DY; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea., Lee KH; Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea., Hyun MS; Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea., Kim HS; Department of Pediatrics, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea., Kim SH; Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Korea., Kwon H; Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Korea., Kim HJ; Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Korea., Park KT; Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea., Bae SH; Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu Catholic University School of Medicine, Daegu, Korea., Ryoo HM; Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu Catholic University School of Medicine, Daegu, Korea., Choi JH; Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea., Ahn MJ; Department of Internal Medicine, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, Korea., Yoon HJ; Department of Internal Medicine, Kyung Hee University Hospital, College of Medicine, Kyung Hee University, Seoul, Korea., Nam SH; Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea., Kim BS; Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea., Seong CM; Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea.
Jazyk:	angličtina
Zdroj:	The Korean journal of internal medicine [Korean J Intern Med] 2022 Jul; Vol. 37 (4), pp. 841-850. Date of Electronic Publication: 2022 Jun 28.
DOI:	10.3904/kjim.2021.468
Abstrakt:	Background/aims: We evaluated the feasibility and long-term efficacy of the combination of cytarabine, idarubicin, and all-trans retinoic acid (ATRA) for treating patients with newly diagnosed acute promyelocytic leukemia (APL). Methods: We included 87 patients with newly diagnosed acute myeloid leukemia and a t(15;17) or promyelocytic leukemia/retinoic acid receptor alpha (PML-RARα) mutation. Patients received 12 mg/m2/day idarubicin intravenously for 3 days and 100 mg/m2/day cytarabine for 7 days, plus 45 mg/m2/day ATRA. Clinical outcomes included complete remission (CR), relapse-free survival (RFS), overall survival (OS), and the secondary malignancy incidence during a 20-year follow-up. Results: The CR, 10-year RFS, and 10-year OS rates were 89.7%, 94.1%, and 73.8%, respectively, for all patients. The 10-year OS rate was 100% for patients that achieved CR. Subjects were classified according to the white blood cell (WBC) count in peripheral blood at diagnosis (low-risk, WBC < 10,000/mm3; high-risk, WBC ≥ 10,000/mm3). The low-risk group had significantly higher RFS and OS rates than the high-risk group, but the outcomes were not superior to the current standard treatment (arsenic trioxide plus ATRA). Toxicities were similar to those observed with anthracycline plus ATRA, and higher than those observed with arsenic trioxide plus ATRA. The secondary malignancy incidence after APL treatment was 2.7%, among the 75 patients that achieved CR, and 5.0% among the 40 patients that survived more than 5 years after the APL diagnosis. Conclusion: Adding cytarabine to anthracycline plus ATRA was not inferior to anthracycline plus ATRA alone, but it was not comparable to arsenic trioxide plus ATRA. The probability of secondary malignancy was low.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu